
Prisys Biotech is a leading contract research organization (CRO) based in Shanghai, China, specializing in preclinical drug development using advanced non-human primate (NHP) technology platforms. The company operates an industrial-scale translational research center with over 5000 square meters of facilities and a capacity for 500+ NHPs, staffed by more than 50 medical and veterinary experts. Prisys offers integrated in vivo study solutions including NHP pharmacology, PK/PD/ADME, safety evaluation, translation research, biosafety research, and MRI-guided drug delivery. Their proprietary NHP disease models and AI-driven behavioral analysis systems provide high translational value for drug R&D, particularly in CNS, immunology, hematology, cardiometabolism, fibrosis, nephrology, respiratory, and ophthalmology disease areas. Prisys emphasizes ethical animal care with AAALAC accreditation and collaborates globally to accelerate new medicine development through innovative translational science and technology.

Prisys Biotech is a leading contract research organization (CRO) based in Shanghai, China, specializing in preclinical drug development using advanced non-human primate (NHP) technology platforms. The company operates an industrial-scale translational research center with over 5000 square meters of facilities and a capacity for 500+ NHPs, staffed by more than 50 medical and veterinary experts. Prisys offers integrated in vivo study solutions including NHP pharmacology, PK/PD/ADME, safety evaluation, translation research, biosafety research, and MRI-guided drug delivery. Their proprietary NHP disease models and AI-driven behavioral analysis systems provide high translational value for drug R&D, particularly in CNS, immunology, hematology, cardiometabolism, fibrosis, nephrology, respiratory, and ophthalmology disease areas. Prisys emphasizes ethical animal care with AAALAC accreditation and collaborates globally to accelerate new medicine development through innovative translational science and technology.